Please login to the form below

Not currently logged in
Email:
Password:

IMI teams with C-Path

Europe’s Innovative Medicines Initiative is to work with US-based C-Path to encourage information sharing 

The Innovative Medicines Initiative (IMI) and the Critical Path Institute (C-Path) have signed a Memorandum of Understanding (MoU) to encourage information sharing between the two organisations.

Europe-based IMI and C-Path, based in the US, share similar objectives focused on accelerating the development of safer, more effective medicines for patients. The organisations bring together scientists and academic institutions, as well as representatives from patient organisations, small and medium-sized companies and regulatory agencies, by forming precompetitive public–private partnerships.

The collaboration will foster increased information sharing regarding each organisation's programmes and create a mechanism to exchange knowledge and develop scientific consensus regarding research and testing methods.

In the key area of drug safety, discussions for such a knowledge exchange are ongoing. The SAFE-T consortium, supported by IMI and the Predictive Safety Testing Consortium led by the Critical Path Institute, are working on the development of new biomarkers to predict, diagnose and monitor drug-induced injury to the liver, the kidneys and the vascular system in the clinical setting. In a statement the organisations said: “Increased collaboration between the international consortia could create important synergies and lead to better results for both projects, for instance, in their interaction with the European and US regulatory authorities EMA and FDA.”

15th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics